Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment

Acharya, 2013, Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study, JAMA Ophthalmol, 131, 1405, 10.1001/jamaophthalmol.2013.4237 Abdel-Rahman, 2017, Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review, Expert Rev Anticancer Ther, 17, 387, 10.1080/14737140.2017.1296765 Abdel-Wahab, 2017, Adverse events in cancer immunotherapy, Adv Exp Med Biol, 995, 155, 10.1007/978-3-319-53156-4_8 Michot, 2016, Immune-related adverse events with immune checkpoint blockade: a comprehensive review, Eur J Cancer, 54, 139, 10.1016/j.ejca.2015.11.016 Haslam, 2020, Estimation of the percentage of us patients with cancer who are eligible for immune checkpoint inhibitor drugs, JAMA Netw Open, 3, e200423, 10.1001/jamanetworkopen.2020.0423 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, 366, 2455, 10.1056/NEJMoa1200694 Sun, 2020, Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition, Ocul Immunol Inflamm, 28, 217, 10.1080/09273948.2019.1577978 Dalvin, 2018, Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects, Retina, 38, 1063, 10.1097/IAE.0000000000002181 Zimmer, 2016, Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy, Eur J Cancer, 60, 210, 10.1016/j.ejca.2016.02.024 Abdel-Wahab, 2016, Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports, PLoS One, 11, e0160221, 10.1371/journal.pone.0160221 Boisseau, 2017, Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy, Eur J Cancer, 83, 28, 10.1016/j.ejca.2017.05.036 Yeh, 2015, Ipilimumab-associated bilateral optic neuropathy, J Neuroophthalmol, 35, 144, 10.1097/WNO.0000000000000217 Papavasileiou, 2016, Ipilimumab-induced ocular and orbital inflammation—a case series and review of the literature, Ocul Immunol Inflamm, 24, 140 Sheldon, 2017, Inflammatory orbitopathy associated with ipilimumab, Ophthalmic Plast Reconstr Surg, 33, S155, 10.1097/IOP.0000000000000509 McElnea, 2014, Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab, Orbit, 33, 424, 10.3109/01676830.2014.949792 Hassanzadeh, 2018, Ipilimumab-induced adenohypophysitis and orbital apex syndrome: importance of early diagnosis and management, Neuroophthalmology, 42, 176, 10.1080/01658107.2017.1368090 Tanaka, 2018, Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery, Radiol Case Rep, 13, 261, 10.1016/j.radcr.2017.11.007 Wilson, 2016, Acute visual loss after ipilimumab treatment for metastatic melanoma, J Immunother Cancer, 4, 66, 10.1186/s40425-016-0170-9 Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, 369, 134, 10.1056/NEJMoa1305133 Ribas, 2015, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, 16, 908, 10.1016/S1470-2045(15)00083-2 Ribas, 2016, Association of pembrolizumab with tumor response and survival among patients with advanced melanoma, JAMA, 315, 1600, 10.1001/jama.2016.4059 Robert, 2014, Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial, Lancet, 384, 1109, 10.1016/S0140-6736(14)60958-2 Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, 369, 122, 10.1056/NEJMoa1302369 Koebnick, 2012, Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data, Perm J, 16, 37, 10.7812/TPP/12-031 Gritz, 2004, Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study, Ophthalmology, 111, 491, 10.1016/j.ophtha.2003.06.014 Suhler, 2008, Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest, Am J Ophthalmol, 146, 890, 10.1016/j.ajo.2008.09.014 Prakash, 2002, Immune disorders and susceptibility to neoplasms, Ochsner J, 4, 107 Hemminki, 2017, Surveillance bias in cancer risk after unrelated medical conditions: example urolithiasis, Sci Rep, 7, 8073, 10.1038/s41598-017-08839-5 Wang, 2019, Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis, JAMA Oncol, 5, 1008, 10.1001/jamaoncol.2019.0393 Davar, 2019, PD-1 immune checkpoint inhibitors and immune-related adverse events: understanding the upside of the downside of checkpoint blockade, JAMA Oncol, 5, 942, 10.1001/jamaoncol.2019.0413 Naing, 2018 Passarelli, 2017, Immune system and melanoma biology: a balance between immunosurveillance and immune escape, Oncotarget, 8, 106132, 10.18632/oncotarget.22190 Bomze, 2019, Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden, JAMA Oncol, 5, 1633, 10.1001/jamaoncol.2019.3221 Norose, 1996, Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease, Br J Ophthalmol, 80, 1002, 10.1136/bjo.80.11.1002 Lavezzo, 2016, Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes, Orphanet J Rare Dis, 11, 29, 10.1186/s13023-016-0412-4 Shi, 2014, Association of HLA-DR4/HLA-DRB1∗04 with Vogt-Koyanagi-Harada disease: a systematic review and meta-analysis, Sci Rep, 4, 6887, 10.1038/srep06887 Diem, 2016, Pembrolizumab-triggered uveitis: an additional surrogate marker for responders in melanoma immunotherapy?, J Immunother, 39, 379, 10.1097/CJI.0000000000000143 Fujimura, 2018, HLA-DRB1∗04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy, J Dermatol, 45, 735, 10.1111/1346-8138.14273 Caspi, 2008, Immunotherapy of autoimmunity and cancer: the penalty for success, Nat Rev Immunol, 8, 970, 10.1038/nri2438 Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med, 373, 23, 10.1056/NEJMoa1504030 Robert, 2015, Pembrolizumab versus ipilimumab in advanced melanoma, N Engl J Med, 372, 2521, 10.1056/NEJMoa1503093 Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, 372, 320, 10.1056/NEJMoa1412082 Berner, 2019, Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer, JAMA Oncol, 5, 1043, 10.1001/jamaoncol.2019.0402 Mackin, 2019, Inflammatory side effects of BRAF and MEK inhibitors, Melanoma Res, 29, 522, 10.1097/CMR.0000000000000599 Sun, 2020, Ophthalmic immune-related adverse events following anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology IRIS(R) Registry, Ophthalmology, 10.1016/j.ophtha.2020.11.001